Polycystic ovary syndrome: the competence of a family doctor

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.67.63-67

Keywords:

polycystic ovary syndrome, comorbid pathology, family doctors, screening, treatment, lifestyle modification

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common diseases in the population of women of reproductive age. Due to the wide range of symptoms, PCOS can affect different body systems and be one of the comorbid diseases during a woman’s life.
A family doctor may suspect the diagnosis of PCOS in a woman of reproductive age if there are symptoms of menstrual irregularities and/or concomitant symptoms of androgen excess, namely acne, hirsutism, etc. According to the Rotterdam criteria, the diagnosis of PCOS can be established if there are two of the following three criteria: hyperandrogenism (established clinically or biochemically), irregular menstrual cycle
(< 9 cycles per year or interval between cycles > 35 days) and polycystic ovaries at the ultrasound study (> 12 antral follicles in one ovary and/or ovarian volume > 10 cm2).
Differential diagnosis of PCOS requires the exclusion of other diseases, most often these are: pregnancy, thyroid gland dysfunction, hyperprolactinemia, Cushing’s syndrome; less often – congenital hyperplasia of the adrenal glands and androgen-secreting tumors. Anthropometric research is also one of the examination of patients with PCOS.
First-line therapy for obese women with PCOS is lifestyle modification through behavioral therapy, moderate physical activity, and healthy eating habits. In addition to lifestyle modification, PCOS treatment should be multitargeted to match each patient’s phenotype, symptoms, personal goals, and expectations, such as desire to become pregnant.
Screening for diabetes, dyslipidemia, hypertension, anemia, and vitamin D deficiency is important in the management of PCOS patients. All patients with a severe or rapidly progressive course, or those with testosterone levels greater than twice the upper limit of normal, should be referred to an endocrinologist or gynecologist to rule out other causes of the condition.

Author Biographies

V.V. Artyomenko, Odesa National Medical University, Odesa

MD, professor, Obstetrics and Gynecology Department

V.I. Velychko, Odesa National Medical University, Odesa

MD, professor, head of the Department of Family Medicine and Polyclinic Therapy, chairman of the Association of Family Medicine of the Odesa Region

D.O. Lahoda, Odesa National Medical University, Odesa

PhD, assistant professor, Department of Family Medicine and Polyclinic Therapy

N.M. Nastradina, Odesa National Medical University, Odesa

PhD, associate professor, Department of Obstetrics and Gynecology

K.O. Nitochko, Odesa National Medical University, Odesa

PhD, associate professor, Department of Obstetrics and Gynecology

References

  1. Sirmans, S.M., Pate, K.A. “Epidemiology, diagnosis, and management of polycystic ovary syndrome.” Clin Epidemiol 6 (2013): 1–13.
  2. Bozdag, G., Mumusoglu, S., Zengin, D., et al. “The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.” Hum Reprod 31 (2016): 2841–55.
  3. Gyliene, A., Straksyte, V., Zaboriene, I. “Value of ultrasonography parameters in diagnosing polycystic ovary syndrome.” Open Med (Wars) 17.1 (2022): 1114–22. DOI: 10.1515/med-2022-0505. PMID: 35799603; PMCID: PMC9210988.
  4. Artyomenko, V.V., Velychko, V.I., Lahoda, D.O. “New approaches to early detection of polycystic ovary syndrome in obese women.” Reproductive endocrinology 4.66 (2022): 20–5.
  5. Forslund, M., Landin-Wilhelmsen, K., Trimpou, P., et al. “Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution.” Hum Reprod Open. 2020.1 (2020): hoz042. DOI: 10.1093/hropen/hoz042. PMID: 31976382; PMCID: PMC6964225.
  6. Krstevska, B., Mishevska, S.J., Nakova, V.V., Serafimoski, V. “Prevalence and Predictors of Impaired Glucose Tolerance and Diabetes Mellitus Type 2 in Patients with Polycystic Ovary Syndrome.” Pril (Makedon Akad Nauk Umet Odd Med Nauki) 42.2 (2021): 61–70. DOI: 10.2478/prilozi-2021-0022. PMID: 34699702.
  7. Royal College of Obstetricians and Gynaecologists. Long-term consequences of polycystic ovary syndrome. Green-top guideline No. 33. London, UK: Royal College of Obstetricians and Gynaecologists (2007).
  8. Kahal, H., Kyrou, I., Uthman, O.A., et al. “The prevalence of obstructive sleep apnoea in women with polycystic ovary syndrome: a systematic review and meta-analysis.” Sleep Breath 24.1 (2020): 339–50. DOI: 10.1007/s11325-019-01835-1. PMID: 31111411; PMCID: PMC7127997.
  9. Gopal, M., Duntley, S., Uhles, M., Attarian, H.“The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome.” Sleep Med 3.5 (2002): 401–4. DOI: 10.1016/s1389-9457(02)00033-3. Available from: [https://www.researchgate.net/publication/9031103_The_role_of_obesity_in_the_increased_of_obstructive_sleep_apnea_syndrome_in_patients_with_polycystic_ovarian_syndrome].
  10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.” Fertil Steril 81 (2004): 19–25.
  11. Velychko, V.I., Mykhailenko, V.L., Lahoda, D.O., et al. “Screening for diabetes and prediabetes: the newest communication opportunities.” Reproductive endocrinology 6.62 (2021): 92–5.
  12. Hart, R., Doherty, D.A. “The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage.” J Clin Endocrinol Metab 100 (2015): 911–9.
  13. Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. “Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.” J Clin Endocrinol Metab 98 (2013): 4565–92.
  14. Treister-Goltzman, Y., Yarza, S., Peleg, R. “Iron Deficiency and Nonscarring Alopecia in Women: Systematic Review and Meta-Analysis.” Skin Appendage Disord 8 (2022): 83–92. DOI: 10.1159/000519952
  15. Conway, G., Dewailly, D., Diamanti-Kandarakis, E., et al. “The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” Eur J Endocrinol 171 (2014): P1–29.
  16. Artyomenko, V., Nastradina, N., Nitochko, K., Altyieva, M. “Hypomenstrual syndrome in adolescent girls as a result of reproductive dysfunction in their mothers: Literature review.” Reproductive Endocrinology 6 (2021): 66–70. DOI: 10.18370/2309-4117.2021.61.66-70
  17. Witchel, S.F., Oberfield, S.E., Peña, A.S. “Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment with Emphasis on Adolescent Girls.” J Endocr Soc 3.8 (2019): 1545–73. DOI: 10.1210/js.2019-00078. PMID: 31384717; PMCID: PMC6676075.
  18. Wharton, S., Lau, D.C.W., Vallis, M., et al. “Obesity in adults: a clinical practice guideline.” CMAJ 192.31 (2020): E875-E891. DOI: 10.1503/cmaj.191707
  19. National Institute for Health and Care Excellence. Obesity in adults: prevention and lifestyle weight management programmes (2016). Available from: [https://www.nice.org.uk/guidance/qs111].
  20. Teede, H.J., Misso, M.L., Costello, M.F., et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (2018). Available from: [https://www.monash.edu/__data/assets/pdf_file/0004/1412644/PCOS_Evidence-Based-Guidelines_20181009.pdf].
  21. Al Wattar, B.H., Fisher, M., Bevington, L., et al. “Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study.” J Clin Endocrinol Metab 106.8 (2021): 2436–46. DOI: 10.1210/clinem/dgab232. Available from: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830055/].
  22. Radosh, L. “Drug treatments for polycystic ovary syndrome.” Am Fam Physician 79.8 (2009): 671–6. PMID: 19405411.
  23. Lucidi, R.S. Polycystic Ovarian Syndrome Guidelines. Available from: [https://emedicine.medscape.com/article/256806-guidelines].
  24. Zehravi, M., Maqbool, M., Ara, I. “Healthy Lifestyle and Dietary Approaches to Treating Polycystic Ovary Syndrome: A Review.” Open Health 3:1 (2022): 60–5.
  25. Lepine, S., Jo, J., Metwally, M., Cheong, Y.C. “Ovarian surgery for symptom relief in women with polycystic ovary syndrome.” Cochrane Database Syst Rev 11 (2017): CD009526. DOI: 10.1002/14651858.CD009526.pub2
  26. Saini, S., et al., “Gaps in knowledge in diagnosis and management of polycystic ovary syndrome.” Fertil Steril 106.3 (2016): e100.
  27. Gibson-Helm, M., Teede, H., Dunaif, A., Dokras, A. “Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome.” J Clin Endocrinol Metab 102.2 (2017): 604–12.
  28. Brakta, S., Lizneva, D., Mykhalchenko, K., et al. “Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?” J Clin Endocrinol Metab 102.12 (2017): 4421–7.
  29. Rudnicka, E., Radowicki, S., Suchta, K. “Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome – a new insight.” Gynecol Endocrinol 32.11 (2016): 931–5.
  30. Villarroel, C., López, P., Merino, P.M., et al. “Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.” Gynecol Endocrinol 31.8 (2015): 625–9.
  31. Salameh, W.A., Redor-Goldman, M.M., Clarke, N.J., et al. “Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.” Fertil Steril 101.4 (2014): 1135–1141.e2.
  32. Lizneva, D., Gavrilova-Jordan, L., Walker, W., Azziz, R. “Androgen excess: Investigations and management.” Best Pract Res Clin Obstet Gynaecol 37 (2016): 98–118.
  33. Lizneva, D., Gavrilova-Jordan, L., Walker, W., Azziz, R. “Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis.” Fertil Steril 106.6 (2016): 1510–1520 e2.
  34. Uysal, G., Sahin, Y., Unluhizarci, K., et al. “Is acne a sign of androgen excess disorder or not?” Eur J Obstet Gynecol Reprod Biol 211 (2017): 21–5.
  35. Carmina, E., Campagna, A.M., Fruzzetti, F., Lobo, R.A. “Amh Measurement Versus Ovarian Ultrasound in the Diagnosis of Polycystic Ovary Syndrome in Different Phenotypes.” Endocrine Practice 22.3 (2016): 287–93.
  36. Cassar, S., Teede, H.J., Moran, L.J., et al. “Polycystic ovary syndrome and anti-Mullerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.” Clin Endocrinol 81.6 (2014): 899–906.
  37. Dewailly, D., Alebić, M.Š., Duhamel, A., Stojanović, N. “Using cluster analysis to identify a homogeneous subpopulation of women with polycystic ovarian morphology in a population of non-hyperandrogenic women with regular menstrual cycles.” Hum Reprod 29.11 (2014): 2536–43.
  38. Kim, J.Y., Tfayli, H., Michaliszyn, S.F., et al. “Anti-mullerian hormone (AMH) in obese adolescent girls with polycystic ovary syndrome (PCOS): cross-sectional and treatment-associated longitudinal changes. Endocrine reviews.” Conference: 98th annual meeting and expo of the endocrine society, ENDO 37.2.1 (2016).
  39. Lauritsen, M.P., Bentzen, J.G., Pinborg, A., et al. “The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.” Hum Reprod 29.4 (2014): 791–801.
  40. Dokras, A., Stener-Victorin, E., Yildiz, B.O., et al. “Androgen Excess-Polycystic Ovary Syndrome Society Position Statement on Depression, Anxiety, Quality of Life and Eating Disorders in Polycystic Ovary Syndrome.” Fertil Steril 109.5 (2018): 888–99.
  41. Pinola, P., Piltonen, T.T., Puurunen, J., et al. “Androgen Profile Through Life in Women with Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study.” J Clin Endocrinol Metab 100.9 (2015.): 3400–7.
  42. Li, J., Eriksson, M., Czene, K., et al. “Common diseases as determinants of menopausal age.” Hum Reprod 31.12 (2016): 2856–64.
  43. Merz, C.N., Shaw, L.J., Azziz, R., et al. “Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome.” J Womens Health (Larchmt) 25.9 (2016): 875–81.
  44. Gabrielli, L., de Almeida Mda, C., Aquino, E.M. “Proposed criteria for the identification of polycystic ovary syndrome following menopause: An ancillary study of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).” Maturitas 81.3 (2015): 398–405.
  45. Heida, K.Y., Bots, M.L., de Groot, C.J., et al. “Cardiovascular risk management after reproductive and pregnancy-related disorders: A Dutch multidisciplinary evidence-based guideline.” Eur J Prev Cardiol 23.17 (2016): 1863–79.

Downloads

Published

2023-03-31

How to Cite

Artyomenko, V., Velychko, V., Lahoda, D., Nastradina, N., & Nitochko, K. (2023). Polycystic ovary syndrome: the competence of a family doctor. REPRODUCTIVE ENDOCRINOLOGY, (67), 63–67. https://doi.org/10.18370/2309-4117.2023.67.63-67

Issue

No. 67 (2023)

Section

Gynecology

License

Copyright (c) 2023 В.В. Артьоменко, В.І. Величко, Д.О. Лагода, Н.М. Настрадіна, К.О. Ніточко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.